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ABSTRACT
Neoadjuvant (preoperative) chemoradiotherapy (CRT) decreases the risk of
rectal cancer recurrence and reduces tumour volume prior to surgery. However,
response to CRT varies considerably between individuals and factors associated
with response are poorly understood. Foxp3+ regulatory T cells (Tregs) inhibit antitumour immunity and may limit any response to chemotherapy and radiotherapy. We
have previously reported that a low density of Tregs in the tumour stroma following
neoadjuvant CRT for rectal cancer is associated with improved tumour regression.
Here we have examined the association between Treg density in pre-treatment
diagnostic biopsy specimens and treatment response, in this same patient cohort. We
aimed to determine whether pre-treatment tumour-infiltrating Treg density predicts
subsequent response to neoadjuvant CRT. Foxp3+, CD8+ and CD3+ cell densities in
biopsy samples from 106 patients were assessed by standard immunohistochemistry
(IHC) and evaluated for their association with tumour regression grade and survival.
We found no association between the density of any T cell subset pre-treatment and
clinical outcome, indicating that tumour-infiltrating Treg density does not predict
response to neoadjuvant CRT in rectal cancer. Taken together with the findings of the
previous study, these data suggest that in the context of neoadjuvant CRT for rectal
cancer, the impact of chemotherapy and/or radiotherapy on anti-tumour immunity
may be more important than the state of the pre-existing local immune response.

Neoadjuvant CRT reduces tumour volume and decreases
the risk of local recurrence [2, 3]. However, response
(degree of regression) varies considerably between
individuals. While approximately 20% of patients have a
pathologic complete response (defined as no viable tumour
cells in the surgical resection specimen), around 60% have
a partial or intermediate response, and approximately 20%
experience little to no regression [4–6]. The benefit of
CRT for this latter patient group is therefore less clear and

INTRODUCTION
Colorectal cancer is the third most common cancer
worldwide, representing almost 10% of all cancer
diagnoses [1]. Rectal cancer accounts for around one
third of colorectal cancer cases. Standard treatment for
locally advanced rectal cancer consists of neoadjuvant
radiotherapy with concurrent 5-fluorouracil (5-FU)-based
chemotherapy (neoadjuvant CRT), followed by surgery.
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factors associated with response are not well understood.
Importantly, the extent of tumour regression following
CRT is associated with improved long-term outcome, even
in the context of potentially curative surgery [7–9].
It is well established that the immune system plays
an important role in cancer control and treatment response
[10, 11]. Infiltration of tumours by T cells is associated
with improved prognosis in many cancers [12–15] and
may even be more prognostic than histological TNM
stage for patients with stage I-III colorectal cancer [16]. In
rectal cancer patients treated with surgery alone, a higher
density of total and CD8+ T cells in the central tumour
and invasive margin is associated with improved diseasefree and overall survival [17], and in neoadjuvantly-treated
rectal cancer, a greater pre-treatment CD8+ T cell infiltrate
predicts good response to CRT [17–19]. In contrast,
tumour infiltration by CD4+ regulatory T cells (Tregs),
which constitutively express the transcription factor
forkhead box protein 3 (Foxp3) and negatively regulate
immune responses, is often associated with poorer clinical
outcome [20–23].
Both chemotherapy and radiotherapy can enhance
anti-tumour immunity through a range of different
mechanisms, including selective depletion of Tregs [24–
28]. We recently reported that, in a cohort of 128 patients
who underwent neoadjuvant CRT and surgery for rectal
cancer at our institution, the presence of fewer Tregs in
the stroma of surgical resection specimens (post-CRT)
was strongly associated with improved tumour regression
[29]. Patients with a low stromal Treg density were over
five times more likely to have a complete pathological
response (pCR) after adjustment for clinical factors.
While this may represent selective Treg depletion in these
patients, an alternate hypothesis is that fewer Tregs in the
local tumour environment prior to treatment may allow
for effective chemoradiotherapy-induced antitumour
immunity.
Here we present an evaluation of Foxp3+, CD8+
and CD3+ cell density in pre-treatment diagnostic
biopsy samples from this same cohort, with the aim of
determining whether pre-CRT T cell density can predict
subsequent treatment response.

all analyses. To minimise sampling bias, samples with a
total analysis area (sum of all fragments) <1mm2 (a further
three patients) were also excluded. Of the remaining 106
cases, median total tissue area analysed per sample was
6 mm2. Moderate, but significant concordance in T cell
subset densities between individual biopsy fragments
selected for analysis was observed (Supplementary
Figure 1B).
Pre-treatment characteristics, treatment response and
infiltrating T cell densities for the 106 patients included in
the analyses are shown in Table 1. The majority of patients
were male and the mean age at time of surgery was 62
years. Most (83%) patients were clinical T stage 3, and
79% were assessed as having lymph node involvement on
pre-treatment imaging. According to the Dworak grading
system [30], 21 patients (20%) had a complete response to
CRT (Dworak grade 4), 38 patients (36%) a good response
(Dworak grade 3), 40 (38%) an intermediate response
(Dworak grade 2) and 7 patients (6%) were classed as
Dworak 1 poor responders.
We observed considerable variation in infiltrating
T cell densities between patients (Table 1, Figure 1 and
Supplementary Figure 1). However, analysis of T cell
subset density by Dworak grade revealed no association
between pre-treatment Foxp3+, CD8+ or CD3+ cell
densities and response to CRT (Figure 2). There was
no significant difference in T cell subset densities when
Dworak 3-4 ‘good’ responders were compared to Dworak
1-2 poor/intermediate responders, or when Dworak 4
complete responders were compared to all other groups
(data not shown). There was a strong positive correlation
between the density of Foxp3+ cells and CD8+ cells within
individual samples (Figure 3A). As expected, densities
of CD8+ and CD3+ cells, and of Foxp3+ and CD3+ cells
were also strongly correlated (Figure 3B and 3C). Ratios
of CD8+ to CD3+ T cells and Foxp3+ to CD8+ T cells were
also assessed for correlation with tumour regression grade,
but no association was found (data not shown).
We next investigated the relationship between
T cell subset densities and pre-treatment clinical and
demographic factors (Table 2). Gender was the only
variable significantly associated with infiltrating T cells,
with a higher density of Foxp3+, and CD8+ cells in biopsies
from female compared to male patients.
Visual inspection of IHC images suggested that
Foxp3+ T cells were located primarily in the stroma,
rarely infiltrating the epithelial tissue (Figure 4A). Linear
regression analysis confirmed an inversely proportional
relationship between Foxp3+ T cell density and estimated
epithelial content (Figure 4C). However, adjusting for
epithelial content did not reveal any association between
Foxp3+ T cell density and Dworak grade (data not shown).
Median follow up duration from surgery for this
patient group was 78 months, with 5-year cancer-specific
survival (CSS) and recurrence-free survival (RFS) of 87%

RESULTS
Diagnostic biopsy samples with sufficient material
remaining for immunohistochemistry (IHC) analysis
were obtained for 113 patients (88% of our originally
reported cohort [29]). Eight cases were stained for Foxp3
and CD8 only. Six cases were judged to be of inadequate
staining quality (detached/folded tissue or high nonspecific background DAB staining) and were subsequently
excluded (five cases for CD3 only and one case for all
stains). Three cases were found to have no invasive
cancer remaining in the sample and were excluded from
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Table 1: Patient characteristics
n = 106
Age, mean (sd)

62 (12.3)

Gender, n (%)
male

77 (73)

female

29 (27)

Distance from anal verge (cm), mean (sd)

7 (3.6)

Weeks between end CRT and surgery, median (IQR)

7 (6, 8)

Pre-treatment clinical T stage, n (%)
T2

7 (7)

T3

86 (83)

T4

11 (11)

NR

2 (2)

Pre-treatment clinical N stage, n (%)
N0

22 (21)

N1-2

82 (79)

NR

2 (2)

Pre-treatment clinical M stage, n (%)
M0

95 (90)

M1-2

10 (9)

NR

1 (1)

Dworak grade, n (%)
4 (pCR)

21 (20)

3

38 (36)

2

40 (38)

1

7 (6)

Foxp3+ cell density (cells / mm2), median (range)

427 (42, 1562)

CD8+ cell density (cells / mm2), median (range)

373 (29, 1814)

CD3 cell density (cells / mm ), median (range)

1104 (108, 2514)*

+

2

Abbreviations: IQR = interquartile range; NR = not recorded; pCR = pathologic complete response
* n = 93 (8 cases were stained for Foxp3 and CD8 only; a further 5 cases were excluded due to poor staining/tissue quality)
and 83% respectively. Kaplan-Meier survival analysis
demonstrated that pre-treatment T cell density had no
prognostic value in this patient group (Figure 5).
These data, together with our previous finding that a
low stromal Foxp3+ Treg density post-CRT was associated
with greater tumour regression in this cohort [29], suggest
that the impact of CRT on anti-tumour immunity may be
more important than the state of the pre-existing local
immune response. We divided the cohort into four groups
according to Treg density in the pre-treatment biopsy
www.impactjournals.com/oncotarget

samples and in the post-treatment stroma (high/high, low/
high, high/low, and low/low). While only 10% of patients
who achieved a Dworak 4 pCR had a stromal Treg density
higher than the median value post-CRT, patients in this
group were equally likely to have a high or low Treg
density pre-CRT (Figure 6). Similarly, while only 14% of
Dworak 1 poor responders had a low stromal Treg density
post CRT, the percentage of patients in this group with
a high vs low pre-CRT Treg density was 43% vs 57%
respectively.
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Figure 1: Identification of T cell subsets in diagnostic biopsy samples by immunohistochemistry. Representative images

(from different patients) demonstrating low (top row), moderate (middle row) and high (bottom row) densities of Foxp3+, CD8+ and CD3+
cells. Scale bar, 100μm.

Figure 2: Pre-CRT T cell density does not predict treatment response. Foxp3+ A., CD8+ B. and CD3+ C. cell densities by
tumour regression (Dworak) grade. P = NS; general linear model. Dots represent individual patients. Line at median.

Figure 3: Correlation between T cell subset densities. Linear regression analyses. Dots represent individual patients. P < 0.05
indicates significant correlation.
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Table 2: T cell subset densities according to pre-treatment clinical and demographic factors
Foxp3+ cell density

Age
Gender
Distance from anal
verge
Clinical T stage

Clinical N stage
Clinical M stage

CD8+ cell density

CD3+ cell density

Low
n (%)

High
n (%)

P

Low
n (%)

High
n (%)

P

Low
n (%)

High
n (%)

P

≥ 65

24 (47)

27 (53)

0.560

24 (47)

27 (53)

0.560

20 (45)

24 (55)

0.353

< 65

29 (53)

26 (47)

29 (53)

26 (47)

27 (55)

22 (45)

Male

44 (57)

33 (43)

44 (57)

33 (43)

36 (55)

30 (45)

Female

9 (31)

20 (69)

9 (31)

20 (69)

11 (41)

16 (59)

≥ 7cm

28 (49)

29 (51)

28 (49)

29 (51)

25 (50)

25 (50)

< 7cm

25 (51)

24 (49)

25 (51)

24 (49)

22 (51)

21 (49)

T2

4 (57)

3 (43)

2 (29)

5 (71)

1 (17)

5 (83)

T3

40 (47)

46 (53)

43 (50)

43 (50)

39(52)

36(48)

T4

8 (73)

3 (27)

7 (64)

4 (36)

6(60)

4(40)

N0

14 (64)

8 (36)

12 (55)

10(45)

10 (48)

11 (52)

N1-2

38 (45)

44 (54)

40 (49)

42 (51)

36 (51)

34 (49)

M0

47 (49)

48 (51)

47 (49)

48 (51)

41 (49)

43 (51)

M1-2

6 (60)

4 (40)

5 (50)

5 (50)

5 (63)

3 (37)

0.017

0.846

0.246

0.150
0.742

0.017

0.846

0.395

0.631
0.975

0.227

0.911

0.207

0.759
0.714

Bold text denotes significant associations (P < 0.05)

Figure 4: Foxp3+ cell density is inversely proportional to epithelial content. A and B. Representative images (from different

patients) demonstrating Foxp3+ cells located in the stroma (A) and CD8+ cells infiltrating the epithelium (B). Scale bar, 50μm. C to E.
Linear regression analyses of T cell subset density by estimated epithelial tissue content across fragments. Dots represent individual
patients. Data represent totals across all fragments analysed. NS = not significant.
www.impactjournals.com/oncotarget
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DISCUSSION

T cell subset densities did not differ according to
clinical tumour or nodal stage, or the presence / absence of
distant metastases as determined by pre-treatment imaging.
The only clinical or demographic variable significantly
associated with T cell subset density was gender, with
females having a more pronounced infiltrate of Foxp3+and
CD8+ cells. While an interesting observation, this finding
is unlikely to be clinically important since there was no
gender-specific difference in CRT response or survival in
this, or in previously studied cohorts [18, 19, 29, 31] (data
not shown).
We were not able to replicate the finding from
previous similar studies that a high density of CD8+ T
cells prior to neoadjuvant treatment is associated with
good response [17–19]. A key difference between these

In this study, we investigated the relationship
between T cell subset density in pre-treatment
diagnostic biopsies and response to neoadjuvant CRT
in 106 patients with locally advanced rectal cancer.
We hypothesised that an existing local anti-tumour
immune response dominated by CD8+ cells rather than
Tregs would ‘set the scene’ for effective CRT-induced
anti-tumour immunity, and therefore better treatment
response. Despite considerable inter-patient variation in
T cell subset densities, we found no association between
Foxp3+, CD8+ or CD3+ cell density (or ratios of T cell
subsets) in pre-treatment biopsies and tumour regression
grade or long-term survival.

Figure 5: Pre-CRT T cell density is not associated with long-term survival. Kaplan-Meier estimates for cancer-specific A-C.
and recurrence-free survival D-F. by T cell subset density. Groups were split at the median value. P = NS; log-rank test.

Figure 6: Foxp3+ cell density pre and post-CRT. Patients with available data at both biopsy and resection (n = 103) were divided

into four groups based on the density of Foxp3+ cells in the pre-treatment biopsy sample and in the stroma at resection (high versus low,
split at the median value). The frequency A. and percentage (A) and B. of patients in each group by Dworak grade.
www.impactjournals.com/oncotarget
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studies and ours is that we assessed T cell subset densities
objectively across entire tissue fragments using image
analysis software (Supplementary Figure 2), whereas the
studies by Teng et al and Yasuda et al determined T cell
subset densities by visual scoring of randomly selected
high power fields [18, 19]. Anitei et al used image analysis
software, but calculated cell density based on the average
of the three most infiltrated areas [17]. Also, over 99% of
our patients received concurrent chemotherapy, compared
to 76% in the study reported by Anitei et al (24% receiving
radiotherapy alone) [17]. Another possible reason for
discordance with these previous studies could be the
different systems used for assessing response to CRT.
While Teng et al also used the Dworak system, Anitei
et al used a modified three-tier grading system based
on tumour-fibrosis ratio [32] and Yasuda et al evaluated
response according to the Japanese Classification of
Colorectal Carcinoma [33]. Importantly, there is inherent
imprecision in current systems used to assess tumour
regression following neoadjuvant therapy due to the
subjective nature of terms used (such as ‘few tumour
cells’, ‘easy to find’ and ‘significant fibrosis’), leaving
them open to individual interpretation. This subjectivity
could also explain the relatively low proportion of patients
classed as Dworak 1 poor responders in our cohort,
compared to some previous studies [4–6].
In another recent study, Shinto et al found a high
CD8/Foxp3 ratio pre-CRT to be predictive of improved
tumour regression [34]. However, patients in that study
received short-course CRT (20 Gy given over 5 days
with concurrent uracil over 7 days) and surgery 30 days
later, rather than long-course CRT (50.4 Gy over 5 weeks
with concurrent 5-FU-based chemotherapy) as received
by patients in our cohort. Complete response is less
common after short-course CRT and tumour regression
can continue for up to 12 weeks following long-course
CRT [35], thus these reported results may not be relevant
to long-course CRT.
In the context of long-course CRT, the impact
of chemotherapy and/or radiotherapy on anti-tumour
immunity may be more important than the state of the
pre-existing local immune response. In this same patient
cohort, we recently demonstrated that a low density
of Foxp3+ Tregs within the tumour stroma following
neoadjuvant CRT was strongly associated with pCR [29].
Indeed, when both pre- and post-treatment Treg density
was taken into account in the current study, while 90%
of the Dworak 4 complete responders had a post-CRT
stromal Treg density below the median value, the number
of patients with a high versus low pre-CRT Treg density
in this group was equal.
Tregs undergo rapid turnover relative to other
T cell subsets and are selectively depleted by several
chemotherapy drugs, including 5-FU [28, 36, 37]. It is
possible that selective depletion of Tregs during CRT
in some patients may create a ‘window of opportunity’
www.impactjournals.com/oncotarget

for enhanced anti-tumour immunity, contributing to
tumour regression. However, we cannot rule out that an
increased presence of Tregs surrounding poor responding
tumours post-CRT simply reflects an immune response
to residual tumour. The anti-tumour immune response
is also inherently complex. It may be that the functional
status of T cells within the tumour microenvironment prior
to CRT, and/or their interaction with other cell types, is
more important than simply the density of the major T cell
subsets. We plan to address this in a second similar cohort.
Although tumour-infiltrating Foxp3+ cells are
associated with poor prognosis in most solid cancers [20–
23], their presence in colorectal cancer has proven to be a
good prognostic factor in several independent studies [38–
40]. Treg expansion in this context may simply represent
an indirect measure of anti-tumour immunity (in response
to CD8+ T cell activation); the densities of these subsets
do often correlate [39, 41, 42]. It has also been proposed
that Tregs limit the pro-tumour effects of Th17-mediated
inflammation, driven by the presence of gut bacteria [43,
44]. Alternatively, the positive impact of Foxp3+ T cells in
the gut may be due to a subset of non-suppressive effector/
memory T cells that express Foxp3 at lower levels.
These are found in higher numbers in colorectal tumours
than in other cancers, but cannot be distinguished from
suppressive Tregs using standard immunohistochemical
methods [45]. A weakness of the current study is that,
as we too were using standard IHC, our staining could
not differentiate Tregs from other Foxp3-expressing cell
subsets.
The study was powered to detect a 15% change
in response rate on the continuum between lowest and
highest cell subset density with 90% power at a 5%
significance level (100 observations required). We cannot
exclude the possibility that more subtle associations with
response could be revealed with a larger cohort.
In conclusion, we show that Foxp3+ cell density in
the tumour microenvironment prior to CRT did not predict
tumour regression in locally advanced rectal cancer.
Further work in this area is required to investigate the
potential role of the immune system in mediating response
to CRT.

MATERIALS AND METHODS
Patients
Consecutive patients with rectal adenocarcinoma
treated between 2006 and 2010 with long-course
neoadjuvant 5-fluorouracil (5-FU)-based CRT and
surgery were identified from our prospectively maintained
institutional database. Clinical data collection, treatment
and follow up have been described previously [29].
Dworak tumour regression grade [30] was assigned by
the gastrointestinal pathologists at the time of routine
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pathology reporting, and subsequently verified by a single
pathologist.
Grade 4: no tumour cells, only fibrotic mass (pCR)
Grade 3: very few (difficult to find microscopically)
tumour cells in fibrotic tissue
Grade 2: dominantly fibrotic changes with few
tumour cells or groups (easy to find)
Grade 1: dominant tumour mass with obvious
fibrosis and/or vasculopathy
Grade 0: no regression

and T cell densities were assessed using the chi-square
test, or Fisher’s exact test where there were fewer than 5
observations in any group. To compare high vs low T cell
subset densities, the group was split at the median value.
Differences and associations were considered statistically
significant where P < 0.05. Median follow up time was
calculated using the reverse Kaplan-Meier method.
Analyses were performed using SAS version 9.4 (SAS
Institute Inc, Cary, NC, USA) and GraphPad Prism version
6.0 (GraphPad software Inc, San Diego, CA, USA).

Immunohistochemistry

Ethical statement

Archived pre-treatment diagnostic biopsy material
(formalin-fixed paraffin-embedded (FFPE) tissue) was
obtained. Where there was sufficient material remaining,
4μm sections were cut and stained for Foxp3, CD8 and
CD3 by standard immunohistochemistry (IHC), as
previously described [29]. Slides were scanned at 40x
magnification using a high-resolution digital scanner
(Aperio Scanscope XT; Leica Biosystems, North
Ryde, NSW, Australia). A specialist gastrointestinal
histopathologist (CH) reviewed corresponding H&E slides
for all cases and selected up to three fragments containing
invasive cancer for digital image analysis (Supplementary
Figure 2A). For each fragment, the proportion of epithelial
tissue was also estimated to the nearest 10% (or 5% if
<10%).

The study was approved by the St John of God
Health Care Human Research Ethics Committee and
conducted in accordance with the Declaration of Helsinki.
All patients gave written informed consent for their
biospecimens and health information to be used for
research purposes.

Abbreviations
5-FU: 5-fluorouracil; CRT: chemoradiotherapy;
FFPE:
formalin-fixed
paraffin-embedded;
IHC:
immunohistochemistry; NS: not significant; pCR:
pathological complete response; TILs: tumour-infiltrating
lymphocytes; Tregs: regulatory T cells
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